GB2496076B - Pharmaceutical compositions comprising a mixture of activated-potentiated forms of a polyclonal antibody to human cannabanoid receptor 1 - Google Patents

Pharmaceutical compositions comprising a mixture of activated-potentiated forms of a polyclonal antibody to human cannabanoid receptor 1

Info

Publication number
GB2496076B
GB2496076B GB1302653.9A GB201302653A GB2496076B GB 2496076 B GB2496076 B GB 2496076B GB 201302653 A GB201302653 A GB 201302653A GB 2496076 B GB2496076 B GB 2496076B
Authority
GB
United Kingdom
Prior art keywords
activated
human
mixture
pharmaceutical compositions
polyclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1302653.9A
Other languages
English (en)
Other versions
GB201302653D0 (en
GB2496076A (en
Inventor
Alexandrovna Sergeeva Svetlana
Fyodorovna Dolgovyh Liudmila
Anatolievna Kheyfets Irina
Leonidovna Dugina Julia
Alexandrovna Zabolotneva Julia
Alexandrovich Tarasov Sergey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2496076(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of GB201302653D0 publication Critical patent/GB201302653D0/en
Publication of GB2496076A publication Critical patent/GB2496076A/en
Application granted granted Critical
Publication of GB2496076B publication Critical patent/GB2496076B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1302653.9A 2010-07-15 2011-07-15 Pharmaceutical compositions comprising a mixture of activated-potentiated forms of a polyclonal antibody to human cannabanoid receptor 1 Expired - Fee Related GB2496076B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
PCT/IB2011/002404 WO2012007847A2 (en) 2010-07-15 2011-07-15 Pharmaceutical compositions and methods of treatment

Publications (3)

Publication Number Publication Date
GB201302653D0 GB201302653D0 (en) 2013-04-03
GB2496076A GB2496076A (en) 2013-05-01
GB2496076B true GB2496076B (en) 2018-05-09

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1302653.9A Expired - Fee Related GB2496076B (en) 2010-07-15 2011-07-15 Pharmaceutical compositions comprising a mixture of activated-potentiated forms of a polyclonal antibody to human cannabanoid receptor 1

Country Status (30)

Country Link
US (1) US8865163B2 (enExample)
EP (1) EP2593477A2 (enExample)
JP (1) JP2013535436A (enExample)
KR (1) KR20140012009A (enExample)
CN (1) CN103124742A (enExample)
AR (1) AR082246A1 (enExample)
AU (1) AU2011278040B2 (enExample)
BR (1) BR112013000841A2 (enExample)
CA (1) CA2805091A1 (enExample)
CL (1) CL2013000098A1 (enExample)
CZ (1) CZ2013104A3 (enExample)
DE (1) DE112011102349T5 (enExample)
DK (1) DK201370078A (enExample)
EA (1) EA029400B1 (enExample)
EE (1) EE05760B1 (enExample)
ES (1) ES2542042R1 (enExample)
FI (1) FI20135146L (enExample)
FR (1) FR2962653A1 (enExample)
GB (1) GB2496076B (enExample)
IT (1) ITTO20110641A1 (enExample)
LT (1) LT5987B (enExample)
MX (1) MX361778B (enExample)
MY (1) MY158183A (enExample)
NO (1) NO20130219A1 (enExample)
NZ (1) NZ606768A (enExample)
PE (1) PE20131338A1 (enExample)
PH (1) PH12013500109A1 (enExample)
SE (1) SE1350179A1 (enExample)
SG (1) SG187037A1 (enExample)
WO (1) WO2012007847A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
FR2962652A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
MX2013000543A (es) 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
FR2962655A1 (fr) * 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et ses utilisations dans les procedes de traitement des troubles du systeme genito-urinaire
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
CN103118707A (zh) * 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 复合药物组合物及对糖尿病和代谢紊乱进行治疗的方法
FR2962909A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire
US20130058981A1 (en) * 2010-07-21 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
CZ2013159A3 (cs) * 2010-08-06 2013-06-12 Iliich Epshtein@Oleg Kombinovaná farmaceutická kompozice a zpusoby lécby a prevence infekcních chorob
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
JP6598844B2 (ja) * 2014-03-27 2019-10-30 バード・ロック・バイオ・インコーポレイテッド ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
JP2019502651A (ja) * 2015-09-30 2019-01-31 バード・ロック・バイオ・インコーポレイテッドＢｉｒｄ Ｒｏｃｋ Ｂｉｏ， Ｉｎｃ． ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
CN114375200A (zh) * 2019-08-29 2022-04-19 奥列格·伊利奇·爱泼斯坦 治疗传染病的药物和方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1550460A1 (en) * 2002-08-02 2005-07-06 Oleg Iliich Epshtein Method for correcting immune responses and medicinal agent
WO2008070305A2 (en) * 2006-10-23 2008-06-12 Eli Lilly And Company 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator
WO2008122618A1 (en) * 2007-04-04 2008-10-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
AU723812B2 (en) 1996-02-12 2000-09-07 Oleg Iliich Epshtein Medicinal preparation and a method of medicinal action on human organism
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
FR2962652A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
MY157564A (en) 2010-07-15 2016-06-30 Epshtein Oleg Lliich Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
US20130058981A1 (en) 2010-07-21 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2012010978A2 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating alzheimer's disease
WO2012014078A2 (en) 2010-07-21 2012-02-02 Olge Iliich Epshtein Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
CN103118707A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 复合药物组合物及对糖尿病和代谢紊乱进行治疗的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1550460A1 (en) * 2002-08-02 2005-07-06 Oleg Iliich Epshtein Method for correcting immune responses and medicinal agent
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
WO2008070305A2 (en) * 2006-10-23 2008-06-12 Eli Lilly And Company 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator
WO2008122618A1 (en) * 2007-04-04 2008-10-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jones et al, "A critical overview of homeopathy", Annals of Internal Medicine, 2003, 138, 393-399 *
Shang et al, "Are the clinical effects of homeopathy placebo effects? Comparative study of placebo-controlled trials of homeopathy and allopathy", The Lancet, 2005, 366, 726-732 *
Vickers et al, "Clinical trials of homeopathy and placebo: Analysis of a scientific debate", The Journal of Alternative and Complementary Medicine, 2000, 6, 49-56 *

Also Published As

Publication number Publication date
FI20135146A7 (fi) 2013-02-15
AU2011278040A1 (en) 2013-03-07
DE112011102349T5 (de) 2013-04-18
EE05760B1 (et) 2016-03-15
NZ606768A (en) 2015-08-28
AR082246A1 (es) 2012-11-21
FI20135146L (fi) 2013-02-15
ES2542042A2 (es) 2015-07-29
CL2013000098A1 (es) 2015-01-16
CZ2013104A3 (cs) 2013-05-29
CA2805091A1 (en) 2012-01-19
AU2011278040B2 (en) 2016-06-02
JP2013535436A (ja) 2013-09-12
GB201302653D0 (en) 2013-04-03
ITTO20110641A1 (it) 2012-01-16
GB2496076A (en) 2013-05-01
SE1350179A1 (sv) 2013-04-12
SG187037A1 (en) 2013-02-28
NO20130219A1 (no) 2013-03-22
ES2542042R1 (es) 2015-10-06
CN103124742A (zh) 2013-05-29
LT5987B (lt) 2014-01-27
BR112013000841A2 (pt) 2016-06-07
PE20131338A1 (es) 2013-11-18
EA029400B1 (ru) 2018-03-30
MY158183A (en) 2016-09-15
PH12013500109A1 (en) 2015-07-03
WO2012007847A2 (en) 2012-01-19
MX2013000545A (es) 2013-10-28
US8865163B2 (en) 2014-10-21
EP2593477A2 (en) 2013-05-22
US20130017202A1 (en) 2013-01-17
KR20140012009A (ko) 2014-01-29
EE201300005A (et) 2013-08-15
MX361778B (es) 2018-12-17
DK201370078A (en) 2013-02-14
EA201300133A1 (ru) 2014-03-31
LT2013015A (lt) 2013-11-25
FR2962653A1 (fr) 2012-01-20
WO2012007847A3 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
GB2496076B (en) Pharmaceutical compositions comprising a mixture of activated-potentiated forms of a polyclonal antibody to human cannabanoid receptor 1
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
PL2593095T3 (pl) (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
PL2453895T3 (pl) (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne
EP2603237A4 (en) ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
EP2658970A4 (en) EXPRESS HUMANIZATION OF ANTIBODIES
IL215131A (en) A mixture of compounds for use in therapy
IL231414B (en) Preparations for the preparation of imaging agents
HU1000069D0 (en) New salts for the preparation of pharmaceutical composition
IL222199A0 (en) Process for preparation of dopo-derived compounds and compositions thereof
IL231485A (en) Oral dosage forms of medicinal preparations are resistant to abuse
IL231482A (en) Oral dosage forms of immediate release vehicles are immune to abuse
IL230463A0 (en) Benzamides, their preparation and pharmaceutical preparations containing them
IL219740A0 (en) Humanized antibodies aganist human il-22ra their preparation and pharmaceutical compositions containing them
ZA201206020B (en) Synthesis of magnolol and its analogue compounds
IL229238A (en) Medicinal preparations of calcium rosostatin
ZA201300500B (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
ZA201300657B (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
LT2654770T (lt) Tenekteplazės farmacinės kompozicijos
IL233189A0 (en) New medical use of p75 receptor agonists
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
TWI560195B (en) Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
EP2683378A4 (en) AMORPHOUS FORM OF A MIXTURE OF LOPINAVIR AND RITONAVIR
HU1000624D0 (en) Novel salts skitable for the preparation of pharmaceutical compositions
PT3326648T (pt) Composições farmacêuticas que compreendem anticorpos humanos para pcsk9

Legal Events

Date Code Title Description
R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20150312

Free format text: EXTENSION ALLOWED

Effective date: 20150521

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20150902

Free format text: EXTENSION ALLOWED

Effective date: 20150922

APTC Appeals to the court

Free format text: APPEAL LODGED; APPEAL AGAINST THE DECISION OF THE COMPTROLLER DATED 29 OCTOBER 2015 WAS LODGED WITH THE PATENTS COURT ON 26 NOVEMBER 2015.

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20190715